CHESTERBROOK, PA — Persevere Therapeutics appointed oncology executive James Barlow to its board as the Chesterbrook-based biotechnology company prepares to begin a Phase 2a trial of its experimental cancer drug …
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.